HENDERSON, NV / ACCESSWIRE / September 24, 2018 / Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, some investors may feel like they missed out. Don't worry, you didn't, there are still plenty of undiscovered gems set to make a name for themselves.
The fears previously plaguing biotech stocks are no longer as big a threat. The government no longer puts companies hiking drug price in their cross hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the remainder of the year and throughout 2019.
We decided to explore some of the top undervalued biotech's on our watch list to help you take advantage of this favorable climate for biotech investors.
While we found many interesting companies, one really stood out: Endonovo Therapeutics, Inc. (ENDV).
This company has been making progress for years. While the company is developing their non-invasive medical device for the treatment of cardiovascular diseases, which have passed pre-clinical with favorable results, the reason we're excited about ENDV is their under the radar SofPulse® technology.
The non-invasive pain reduction treatment could render troublesome opioid prescriptions irrelevant. The company just released news of having secured nationwide sales, marketing and distribution.
Now may be just the time to act on ENDV before the revenues start rolling in.
Biotechs and cannabis companies to look at include: Endonovo Therapeutics, Inc. (ENDV), Cronos Group, Inc. (CRON), Aurora Cannabis (ACBFF), Rubius Therapeutics, Inc. (RUBY) and CEL-SCI Corporation (CVM).
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $18.61M Share Price: $0.05
Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a sales and marketing agreement with Magniant, LLC for the distribution of SofPulse®, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Alan Collier, Endonovo Chief Executive Officer, stated, ''We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our SofPulse® device on a national level.''
Cronos Group, Inc. (CRON)
Market Cap: $2.21B Share Price: $12.51
Canadian cannabis company Cronos Group Inc. is partnering with Aleafia Health Inc. in a medical marijuana study aiming to improve the management and treatment of insomnia and daytime sleepiness. The study will be partly funded by Peace Naturals Project Inc., a licensed producer of medical marijuana that is wholly owned by Cronos. Aleafia is a medical marijuana company that is focused on patient care from "seed" to "sale" with more than 50,000 patients. Canada is preparing to fully legalize cannabis for adult recreational and medical use on Oct. 17.
Aurora Cannabis (ACBFF)
Market Cap: $8.82B Share Price: $9.22
Aurora Cannabis Inc. announced that it has scheduled its conference call to discuss the results for its fourth quarter ended June 30, 2018. The call will be hosted on Tuesday, September 25 th, 2018 at 11:00 a.m. Eastern Time by Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley , Chief Corporate Officer followed by a question and answer period.
Rubius Therapeutics, Inc. (RUBY)
Market Cap: $1.80B Share Price: $22.82
Rubius Therapeutics, Inc. (RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, October 2, 2018, at 9:00 a.m. ET.
A live audio webcast will be available within the Investor and News section of the Rubius Therapeutics' website. An archived replay will be accessible for 90 days following the event.
Acadia Pharmaceuticals, Inc. (ACAD)
Market Cap: $2.52B Share Price: $20.17
The Food and Drug Administration assigned ACADIA Pharmaceuticals Inc.'s Nuplazid a positive safety profile Thursday, sending shares soaring 27 percent.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-two thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting. LLC,For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC